scholarly journals Correlation Between Cyclin D1 Expression With Different Pathological Changes in Colorectum Patients

2022 ◽  
Author(s):  
Hanaa Ibrahim Salih Mohammed ◽  
Mohammed Abdelgader Elsheikh ◽  
Alkhair Idris
Keyword(s):  
Colorectal Cancer ◽  
Cyclin D1 ◽  
Cell Cycle Progression ◽  
Medical Center ◽  
Tumor Grade ◽  
Vital Role ◽  
Pathological Changes ◽  
Pathological Alteration ◽  
Paraffin Block ◽  
Colorectal Cancer Patients

Abstract Background: Cyclin D1 plays a vital role in cancer cell cycle progression and is overexpressed in many human cancers, including colorectal cancer. Objectives:This study was aimed to detect cyclin D1 in colorectal cancer patients and to correlate cyclin D1 expression with different pathological changes in colorectum.Methods: Tissues microarray paraffin block with 48 colorectal cancer samples were retrieved from the archives of Elrahma Medical Center. The cyclin D1 was analyzed.Results:Cyclin D1 did not correlate with pathological alterations and with tumor grade.Conclusion:Results indicated that; cyclin D1 not correlates with pathological alteration of colorectal cancer.

scholarly journals Influence of Postoperative Changes in Sarcopenia on Long-Term Survival in Non-Metastatic Colorectal Cancer Patients

Cancers ◽  
2021 ◽  
Vol 13 (10) ◽  
pp. 2410
Author(s):  
Chungyeop Lee ◽  
In-Ja Park ◽  
Kyung-Won Kim ◽  
Yongbin Shin ◽  
Seok-Byung Lim ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Cancer Patients ◽  
Medical Center ◽  
The Body ◽  
Term Survival ◽  
Postoperative Changes ◽  
Asan Medical ◽  
Colorectal Cancer Patients

The effect of perioperative sarcopenic changes on prognosis remains unclear. We conducted a retrospective cohort study with 2333 non-metastatic colorectal cancer patients treated between January 2009 and December 2012 at the Asan Medical Center. The body composition at diagnosis was measured via abdominopelvic computed tomography (CT) using Asan-J software. Patients underwent CT scans preoperatively, as well as at 6 months–1 year and 2–3 years postoperatively. The primary outcome was the association between perioperative sarcopenic changes and survival. According to sarcopenic criteria, 1155 (49.5%), 890 (38.2%), and 893 (38.3%) patients had sarcopenia preoperatively, 6 months–1 year, and 2–3 years postoperatively, respectively. The 5-year overall survival (OS) (95.8% vs. 92.1%, hazard ratio (HR) = 2.234, p < 0.001) and 5-year recurrence-free survival (RFS) (93.2% vs. 86.2%, HR = 2.251, p < 0.001) rates were significantly lower in patients with preoperative sarcopenia. Both OS and RFS were lower in patients with persistent sarcopenia 2–3 years postoperatively than in those who recovered (OS: 96.2% vs. 90.2%, p = 0.001; RFS: 91.1% vs. 83.9%, p = 0.002). In multivariate analysis, postoperative sarcopenia was confirmed as an independent factor associated with decreased OS and RFS. Pre- and postoperative sarcopenia and changes in the condition during surveillance were associated with oncological outcomes.

scholarly journals Exosomal proteases in colorectal cancer

2019 ◽  
Vol 5 (4) ◽  
pp. 117-126 ◽  
Author(s):  
E. A. Zambalova ◽  
M. R. Patysheva ◽  
A. A. Dimcha ◽  
S. N. Tamkovich ◽  
A. E. Grigor’eva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Blood Plasma ◽  
Metabolic Disorders ◽  
Tumor Grade ◽  
20S Proteasome ◽  
A Disintegrin And Metalloproteinase ◽  
Colorectal Cancer Patients ◽  
And Control ◽  
Edta Blood ◽  
In Blood Plasma

The objectiveis to evaluate the level of ADAM10 and ADAM17 (a disintegrin and metalloproteinase) proteases, as well as 20S-proteasomes in blood plasma exosomes of patients with colorectal cancer.Materials and methods. The study included 60 patients with colorectal cancer (T2–4N0–2M0–1) and 10 control patients. The material for the study was EDTA blood plasma. Exosomes of blood plasma were isolated by ultrafiltration with ultracentrifugation. The level of tetraspanin-associated (ADAM10 and ADAM17) and tetraspanin-non-associated (20S-proteasome) proteases was evaluated by flow cytometry and Western blotting.Results.A twice negative subpopulation (ADAM10–/ADAM17–) predominated in blood plasma exosomes of colorectal cancer patients and control patients. The level of ADAM10+/ADAM17– exosomes was significantly higher in the exosomes of the plasma of control patients. There were no significant differences between the ADAM10/ADAM17 subpopulations and the 20S-proteasome level, depending on sex, age and tumor grade. A decrease in the ADAM10+/ADAM17– subpopulation was found in patients with metastatic colorectal cancer with hematogenous metastases compared with patients with T2–4N1–2M0 and 20S-proteasome compared to T2–4N0M0. A decrease in ADAM10–/ ADAM17+ exosomes and 20S-proteasomes level was found in exosomes of patients with colorectal cancer with a metabolic syndrome  in comparison with patients without metabolic disorders.

Efficacy and tolerability of oxycodone for oxaliplatin-induced peripheral neuropathy and the extension of folfox therapy in colorectal cancer patients.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 196-196
Author(s):  
Makoto Nagashima ◽  
Mitsuru Ooshiro ◽  
Ayako Moriyama ◽  
Kengo Kadoya ◽  
Ayami Sato ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Peripheral Neuropathy ◽  
Medical Center ◽  
Sensory Neuropathy ◽  
Clinical Settings ◽  
Therapeutic Effects ◽  
The Common ◽  
Grade 3 ◽  
Colorectal Cancer Patients ◽  
Experienced Grade

196 Background: The oxaliplatin-based regimen FOLFOX is widely used to treat patients with advanced colorectal cancer (CRC). However, dose-limiting toxicity after continuous oxaliplatin administration can lead to peripheral neuropathy. Several agents, including opioids, that have been employed to treat oxaliplatin-induced peripheral neuropathy (OIPN) have been examined in clinical settings regarding their protective and therapeutic effects. However, the pharmacotherapy of these agents has not yet been established. Therefore, we investigated the efficacy and tolerability of oxycodone for OIPN and subsequently with FOLFOX therapy in CRC patients. Methods: This was a single-center retrospective study of 64 CRC patients who underwent FOLFOX therapy at the Toho University Sakura Medical Center (Sakura, Japan). Controlled-release (CR) oxycodone was concomitantly administered to 29 patients (OXY group), whereas the additional 35 patients (non-OXY group) were not given oxycodone during the FOLFOX treatment course. The incidence and severity of OIPN and the number of FOLFOX cycles were measured and compared between the two groups. Neurological toxicities were assessed according to the Common Terminology Criteria for Advanced Events, version 3.0. Results: All study patients had OIPN. Most patients experienced grade 1 or 2 sensory neuropathy. Grade 3 sensory neuropathy was observed in two patients in the non-OXY group. All patients in the OXY group completed the scheduled FOLFOX therapy, whereas FOLFOX therapy was discontinued in ten patients in the non-OXY group due to severe peripheral neuropathy. The median numbers of FOLFOX cycles in the OXY and non-OXY groups were 13 (range, 6–46) and 7 (range, 2–18), respectively (P < 0.05). The median cumulative oxaliplatin doses were 1072.3 mg/m2 (range, 408.7–3385.3 mg/m2) in the OXY group and 483.0 mg/m2 (range 76.2–1414.1 mg/m2) in the non-OXY group (P < 0.05). Conclusions: Our findings indicate that CR oxycodone might attenuate the severity of OIPN and extend the use of FOLFOX therapy.

Cyclin D1 level, ploidy status, and S-phase fraction in colorectal cancer patients

2015 ◽  
Vol 35 (2) ◽  
pp. 144-149
Author(s):  
Amira M. Raafat ◽  
Mahmoud T. Elsabah Hussein ◽  
Hend F. Abdelfattah ◽  
Maged M. El Sherbiny ◽  
Noha I. Mohamed ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cyclin D1 ◽  
Cancer Patients ◽  
S Phase ◽  
Phase Fraction ◽  
Colorectal Cancer Patients ◽  
Ploidy Status

Establishment of a minimally invasive program at a Veterans' Affairs Medical Center leads to improved care in colorectal cancer patients

2009 ◽  
Vol 198 (5) ◽  
pp. 685-692 ◽  
Author(s):  
Jonathan A. Wilks ◽  
Courtney J. Balentine ◽  
David H. Berger ◽  
Daniel Anaya ◽  
Samir Awad ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Minimally Invasive ◽  
Cancer Patients ◽  
Medical Center ◽  
Veterans Affairs ◽  
Colorectal Cancer Patients

scholarly journals Cyclin A and cyclin D1 as significant prognostic markers in colorectal cancer patients

2004 ◽  
Vol 4 (1) ◽  
Author(s):  
Abeer A Bahnassy ◽  
Abdel-Rahman N Zekri ◽  
Soumaya El-Houssini ◽  
Amal MR El-Shehaby ◽  
Moustafa Raafat Mahmoud ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cyclin D1 ◽  
Cancer Patients ◽  
Prognostic Markers ◽  
Cyclin A ◽  
Colorectal Cancer Patients

scholarly journals Metadherin (MTDH) overexpression significantly correlates with advanced tumor grade and stages among colorectal cancer patients

2021 ◽  
Author(s):  
Aimen Sultan ◽  
Namood-E Sahar ◽  
Syeda Kiran Riaz ◽  
Javeria Qadir ◽  
Shahzad Hussain Waqar ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Tumor Grade ◽  
Advanced Tumor ◽  
Colorectal Cancer Patients

scholarly journals Insight of microRNA role in Colorectal Cancer

2020 ◽  
Vol 3 (1) ◽  
Author(s):  
Kwan-Liang Lye ◽  
Loh Teng-Hern Tan ◽  
Hui-Min Yap
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Early Stage ◽  
Good Prognosis ◽  
Vital Role ◽  
Colorectal Carcinogenesis ◽  
High Association ◽  
Diagnosis And Prognosis ◽  
Mirnas Expression ◽  
Colorectal Cancer Patients

The colorectal cancer is among the most predominant cancer in the world including Malaysia. Numerous factors could contribute towards colorectal carcinogenesis and one of the factors is genetic predisposition. Mutations in the V-KiRas2 (Kras) oncogene have been implicated in 30-50% of the colorectal cancer patients and usually lead to poorer prognosis. The challenging ability for the early detection of colorectal cancer still poses an enormous challenge to oncologist as there are limited or no signs or symptoms in the early stage of colorectal cancer. Many studies were conducted hoping to further understand colorectal cancer for a better diagnosis and prognosis. As early detection of colorectal cancer frequently leads to good prognosis. The gold standard for prognosis depends on the stage of the tumor at the time of diagnosis. Lately a group of small, non-coding RNAs termed microRNAs (miRNAs) exhibited capable outcomes in cancer research. Numerous miRNAs were discovered to play a key role in regulatory mechanism in numerous cancers. Differential miRNAs expression among tumors and non-tumor controls are highly valuable in recognizing miRNAs that could have vital role in carcinogenesis. Recently some miRNAs were discovered to play a vital role in colorectal carcinogenesis. Thus, miRNAs have emerged as highly useful tool for scientists to comprehend carcinogenesis better. For example, miR-21 and miR-106a were highly expressed in colorectal cancer. While miRNAs including miR-17-92 cluster, miR-21, miR-34, miR-135 and miR-196a also exhibited high association with colorectal cancer. Therefore, this article aims to provide insight of miRNAs role in colorectal cancer for a better understanding of this disease.

Chromogranin-A Expression in Neoplastic Neuroendocrine Cells and Prognosis in Colorectal Cancer

1996 ◽  
Vol 82 (4) ◽  
pp. 390-393 ◽  
Author(s):  
Giovanni Battista Secco ◽  
Elisabetta Campora ◽  
Roberto Fardelli ◽  
Gabriella Lapertosa ◽  
Francesca De Lucchi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Patients ◽  
Chromogranin A ◽  
Colorectal Adenocarcinoma ◽  
Tumor Grade ◽  
Neuroendocrine Cells ◽  
Human Gastrointestinal Tract ◽  
Curative Surgery ◽  
Group Iii ◽  
Colorectal Cancer Patients

Aims Chromogranin-A (CG), a cytoplasmic glycoprotein, is one of the markers most frequently used to identify the presence of neuroendocrine cells in the human gastrointestinal tract. Several authors have identified a subgroup of colorectal cancer patients with a severe prognosis whose tumors contained neuroendocrine CG-positive cells. In the present study, CG expression in 100 patients with colorectal adenocarcinoma treated from January 1983 to December 1988 with potentially curative surgery was analyzed and correlated with other prognostic factors and 5-year survival rate. Methods Samples tested immunohistochemically for CG were divided into three groups: I) negative; II) less than 1 CG-positive cell/mm2; III) more than 1 CG-positive cell/mm2. Results Of 100 patients with primary colorectal adenocarcinoma, 79% had tumors comprised of CG-negative cells, 17% had rare CG-positive cells, and 4% of cases could be classified in group III. No significant relation between CG expression and location of primary tumor, bowel wall infiltration, stage of disease or tumor grade according to Broders and Jass was observed. The 5-year survival was 53% and 52% for CG-positive and CG-negative lesions, respectively. Survival of patients with Dukes-Kirklin stage C and D was comparable in patients with CG-positive (33.3%) and CG-negative (30%) tumors. Conclusions CG expression cannot, at present, be recommended as a marker to identify prognostic subgroups in colorectal cancer patients.

Sign in / Sign up

Export Citation Format

Share Document